Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 8/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP3 | P08254 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14898392 | 0.93 | CTSS (0.38) | TAS1R3TAS1R1TAS1R2CTSSMMP2 | |
| SCHEMBL19790147 | 0.93 | CTSS (0.38) | TAS1R3TAS1R1TAS1R2CTSSMMP2 | |
| SCHEMBL10065865 | 0.78 | CTSS (0.41) | TAS1R3TAS1R1TAS1R2CTSSMMP2 | |
| SCHEMBL14949074 | 0.75 | CTSS (0.37) | TAS1R3TAS1R1TAS1R2CTSSMMP2 | |
| SCHEMBL14010002 | 0.74 | TAS1R3 (0.36) | TAS1R3TAS1R1TAS1R2CTSSMMP2 | |
| SCHEMBL18855074 | 0.70 | TAS1R3 (0.38) | TAS1R3TAS1R1TAS1R2CTSS | |
| SCHEMBL20364905 | 0.70 | HDAC3 (0.38) | — | |
| SCHEMBL8301882 | 0.69 | OPRM1 (0.39) | OPRD1 | |
| SCHEMBL22679571 | 0.69 | CTSS (0.33) | CTSSMMP2MMP3MMP1 | |
| SCHEMBL19369908 | 0.69 | MAOB (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | TAS1R3 1554/4885TAS1R1 1031/4885TAS1R2 834/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TAS1R3 1554/4885TAS1R1 1031/4885TAS1R2 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.